Skip to main content

Table 2 Mean (SD) BMD (g/cm2) for both groups in all gruen zones

From: Bone turnover and periprosthetic bone loss after cementless total hip arthroplasty can be restored by zoledronic acid: a prospective, randomized, open-label, controlled trial

Gruen zones

1

2

3

4

5

6

7

Delta

Baseline

 ZA group

0.64(0.14)

1.26(0.21)

1.52(0.24)

1.63(0.19)

1.57(0.19)

1.24(0.21)

0.96(0.19)

1.15(0.16)

Control

0.64(0.16)

1.24(0.22)

1.53(0.21)

1.66(0.21)

1.61(0.23)

1.25(0.22)

0.97(0.24)

1.15(0.17)

  p-value

0.863

0.778

0.779

0.522

0.446

0.951

0.830

0.968

12 weeks

 ZA group

0.74(0.38)

1.46(0.28)

1.69(0.88)

1.73(0.35)

1.75(0.58)

1.40(0.21)

1.09(0.22)

1.38(0.60)

 Control

0.59(0.14)

1.28(0.21)

1.50(0.21)

1.61(0.21)

1.61(0.22)

1.23(0.23)

0.88(0.20)

1.16(0.14)

  p-value

0.060

0.010a

0.276

0.142

0.238

0.009a

0.001a

0.077

6 months

 ZA group

0.65(0.14)

1.40(0.17)

1.55(0.17)

1.68(0.19)

1.62(0.27)

1.40(0.19)

1.04(0.25)

1.26(0.12)

 Control

0.59(0.15)

1.31(0.26)

1.51(0.22)

1.62(0.23)

1.63(0.23)

1.26(0.23)

0.84(0.30)

1.17(0.16)

  p-value

0.109

0.144

0.529

0.301

0.922

0.021a

0.008a

0.021a

1 year

 ZA group

0.66(0.15)

1.38(0.19)

1.50(0.24)

1.68(0.19)

1.66(0.16)

1.40(0.22)

1.01(0.27)

1.25(0.13)

 Control

0.54(0.20)

1.19(0.38)

1.44(0.38)

1.54(0.38)

1.51(0.39)

1.20(0.36)

0.80(0.30)

1.11(0.28)

  p-value

0.021a

0.035a

0.434

0.096

0.057

0.014a

0.011a

0.021a

2 years

 ZA group

0.67(0.15)

1.38(0.20)

1.49(0.25)

1.68(0.19)

1.65(0.20)

1.44(0.21)

1.01(0.27)

1.26(0.13)

 Control

0.55(0.15)

1.35(0.77)

1.51(0.23)

1.59(0.23)

1.62(0.21)

1.21(0.24)

0.78(0.22)

1.14(0.15)

  p-value

0.013a

0.870

0.786

0.167

0.612

0.001a

0.003a

0.011a

  1. astatistically significant difference between ZA and control groups
  2. BMD bone mineral density, SD standard deviation, ZA zoledronic acid